Journal of Clinical Microbiology, November 1999, p. 3707-3710, Vol. 37, No. 11
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555-0740
Received 18 March 1999/Returned for modification 20 May 1999/Accepted 26 July 1999
In this study, disk diffusion testing with ceftizoxime and
cefuroxime was evaluated for use in predicting the susceptibility of
Streptococcus pneumoniae to ceftriaxone and cefotaxime. Of the 194 isolates included in this study, 138 were susceptible, 34 were
intermediate, and 22 were resistant to cefotaxime by MIC testing; 138 isolates were susceptible, 35 were intermediate, and 21 were resistant
to ceftriaxone by MIC testing. A zone of inhibition around the
cefuroxime disk of
32 mm correctly categorized 101 of 138 isolates as
susceptible to cefotaxime and ceftriaxone. A zone of inhibition around
the ceftizoxime disk of
26 mm correctly categorized 111 of 138 isolates as susceptible to cefotaxime and 114 of 138 as susceptible to
ceftriaxone. We conclude that disk diffusion can separate S. pneumoniae isolates susceptible to ceftriaxone and cefotaxime
from those that are not susceptible. Isolates not falling into the
susceptible category by disk diffusion require additional testing to
determine the MIC.
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|